Label-free nanoplasmonic sensing of tumor-associate autoantibodies for early diagnosis of colorectal cancer

Abstract

Colorectal cancer is treatable and curable when detected at early stages. However there is a lack of less invasive and more specific screening and diagnosis methods which would facilitate its prompt identification. Blood circulating autoantibodies which are immediately produced by the immune system at tumor appearance have become valuable biomarkers for preclinical diagnosis of cancer. In this work, we present the rapid and label-free detection of colorectal cancer autoantibodies directly in blood serum or plasma using a recently developed nanoplasmonic biosensor. Our nanoplasmonic device offers sensitive and real-time quantification of autoantibodies with excellent selectivity and reproducibility, achieving limits of detection around 1 nM (150-160 ng·mL

Building of a flexible microfluidic plasmo-nanomechanical biosensor for live cell analysis

“…The height and flexibility of the nanopillars can help to better expose the LSPR of the Au nanodisks to the dielectric environment, improving the access of the glycerol molecules, thereby influencing the sensitivity. The obtained sensitivity values in bulk agreed with reported values 20,[34][35][36] accrediting the feasibility of our devices for sensing applications.…”

“…In regard to the real-time monitoring tools, Localized Surface Plasmon Resonance (LSPR) is a highly sensitive and cost-effective optical technique for label-free biosensing, widely demonstrated in the literature, for example, for the detection of gluten peptides or tumor-associated autoantibodies. 19,20 Owing to the high sensitivity of LSPR to local refractive index changes near the metal surface, the LSPR change can be used to study the cell behaviour and, thereby, to study the cell integrin-ECM linkage. On other hand, plasmonic nanostructures can be fabricated over polymer nanostructures to provide them height and flexibility.…”

Gold-Loaded Nanoporous Ferric Oxide Nanocubes with Peroxidase-Mimicking Activity for Electrocatalytic and Colorimetric Detection of Autoantibody

“…In contrast, serum autoantibodies are relatively more stable (i.e., longer half-lives due to limited proteolysis and clearance) and present as large quantities in clinical samples and therefore they have been used as circulating reporters for the early or pre-clinical detection of various cancers including ovarian, lung, and breast cancer. 30,31,32,33,34 It is also important to note that, with the progression of the cancer (stages), the amount of autoantibody (produced) compared to that of TAAs is highly significant and readily detectable with the conventional detection techniques. 35 Most of the widely used methods for serum autoantibody detection are mainly based on ELISA or protein arrays that employ HRP conjugated protein specific secondary antibodies to read the target autoantibody.…”

Label-free plasmonic biosensors for point-of-care diagnostics: a review

“…By analyzing clinical samples from different healthy individuals and cancer patients before and after treatment, they demonstrated that the monitoring of these proteins could be validated as a biomarker for non-small cell lung cancer diagnosis 35 . In another work, Soler et al proposed a nanoplasmonic biosensor for the detection of novel tumor autoantibodies in serum for diagnosis of colorectal cancer at early stages, which could reduce the necessity of colonoscopies and be implemented as POC testing for population screening 36 . Inflammatory processes are also a major disorder that affects most of the population and might be caused by numerous malignancies.…”